# Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

> **NCT06114004** · PHASE2 · RECRUITING · sponsor: **Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas** · enrollment: 88 (estimated)

## Conditions studied

- Sarcoma,Soft Tissue

## Interventions

- **DRUG:** Selinexor 20 MG
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06114004
- **Lead sponsor:** Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-28
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2025-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06114004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06114004, "Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06114004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*